Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patientsSemaglutide helps resolve liver inflammation in patients with MASH

British journal of clinical pharmacology Published August 1, 2026 Study authors: Peng Tzu-Rong, Lin Hung-Hong, Tseng Tzu-Ling, Wu Ta-Wei, Chao You-Chen PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider semaglutide for MASH resolution and fat reduction, noting its inconsistent effect on fibrosis progression.

This meta-analysis evaluated the efficacy of semaglutide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The study included 1908 patients to assess histological outcomes, imaging markers, and biochemical indicators.

Key findings indicate that semaglutide significantly improved MASH resolution without worsening fibrosis (OR 3.48; 95% CI: 2.68-4.53; p <.00001). Additionally, patients showed a significant increase in relative liver fat reduction of $≥$30% (OR 7.16; 95% CI: 3.08-16.64; p <.00001) and a decrease in liver stiffness (MD -1.25 kPa; 95% CI: -2.18 to -0.32; p =.009). Significant reductions were also observed in biochemical markers including AST, ALT, and cholesterol.

However, the pooled analysis for fibrosis improvement ($≥$1 stage) did not reach statistical significance (OR 1.17; 95% CI: 0.49-2.80; p =.72). The authors note that anti-fibrotic efficacy appears to be both stage-dependent and time-dependent. Semaglutide is associated with a higher risk of gastrointestinal-related adverse events (RR = 1.83; 95% CI: 1.20-2.79), though no significant difference was found in the risk of serious adverse events (RR = 1.07; 95% CI: 0.82-1.39). Clinical application is currently most supported for resolving steatohepatitis and improving biochemical markers, particularly in non-cirrhotic stages.

How this fits prior evidence

This meta-analysis extends the evidence regarding semaglutide's role in liver disease. It confirms previous findings that semaglutide improves NASH resolution and metabolic improvement. Specifically, it reinforces the observation that while semaglutide effectively addresses steatohepatitis and biochemical markers, its impact on fibrosis remains uncertain or is limited by stage and duration.

Living with a fatty liver (MASH) means dealing with ongoing inflammation and the risk of permanent scarring. A large review of data from 1,908 patients looked at how semaglutide affects these conditions. The study found that semaglutide significantly improved MASH resolution without making the underlying tissue damage worse. It also led to a major increase in people seeing a 30% reduction in liver fat.

While the drug helped reduce liver stiffness and improved key blood markers like cholesterol, the results were more mixed regarding scarring. The study did not find a statistically significant improvement in fibrosis (scarring) across the whole group. This is likely because the effectiveness of reversing scars depends heavily on how much scarring is already present and how long the treatment lasts.

Safety was also tracked closely. Patients taking semaglutide had a higher risk of stomach-related issues, but there was no significant difference in serious medical emergencies compared to the control group. These findings suggest that while the drug works well for inflammation and fat reduction, its ability to fix deep scarring is limited by time and the current stage of the disease.

What this means for you:

Semaglutide effectively reduces liver fat and inflammation, but its ability to reverse scarring depends on timing.

Common questions

Does semaglutide help with liver fat?

Yes. The study found a significant increase in patients who achieved a reduction of at least 30% in liver fat. It also showed that the medication effectively resolves steatohepatitis, which is the inflammation caused by fat buildup in the liver.

Can semaglutide reverse liver scarring?

The results for scarring are mixed. While it did not show a statistically significant improvement in fibrosis across the whole group, its ability to reduce scarring may depend on how much scarring is already present and how long the patient takes the medication.

Are there side effects to using semaglutide for liver issues?

Patients taking semaglutide had a higher risk of gastrointestinal-related issues, such as stomach problems. However, there was no significant difference in the risk of serious adverse events compared to those who did not take the medication.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedAug 2026

PMID42273973

View Original Abstract ↓

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are major health burdens. Previous reviews of semaglutide found inconsistent fibrosis improvement. This study aims to provide updated evidence on the efficacy and safety of semaglutide in MASH through a systematic review and meta-analysis. METHODS: Following PRISMA guidelines (PROSPERO: CRD420261288562), we searched databases through 8 January 2026. Ten studies (n = 1908) were analysed. Primary outcomes were histological MASH resolution and fibrosis improvement; secondary outcomes included liver stiffness and biochemical markers. RESULTS: Semaglutide significantly improved MASH resolution without worsening fibrosis (OR 3.48; 95% CI: 2.68-4.53; p < .00001). However, pooled fibrosis improvement (≥1 stage) was not statistically significant (OR 1.17; 95% CI: 0.49-2.80; p = .72). Radiologically, semaglutide reduced liver stiffness (MD -1.25 kPa; 95% CI: -2.18 to -0.32; p = .009) and increased relative liver fat reduction of ≥30% (OR 7.16; 95% CI: 3.08-16.64; p < .00001). Significant reductions in AST, ALT and cholesterol were also observed. Regarding safety, semaglutide was associated with a higher risk of gastrointestinal-related adverse events (RR = 1.83; 95% CI: 1.20-2.79) compared with the control group, but no significant difference was observed in the risk of serious adverse events (RR = 1.07; 95% CI: 0.82-1.39). CONCLUSION: Semaglutide effectively resolves steatohepatitis and improves biochemical and imaging markers. However, its anti-fibrotic efficacy appears stage-dependent and time-dependent, with significant histological reversal primarily observed in non-cirrhotic stages within current trial durations.

Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patientsSemaglutide helps resolve liver inflammation in patients with MASH

How this fits prior evidence

Common questions

Study Details

Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis

TyG Index Linked to Higher Fatty Liver Risk

Clinical research that matters. Delivered to your inbox.

Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patientsSemaglutide helps resolve liver inflammation in patients with MASH

How this fits prior evidence

Common questions

More on Metabolic Dysfunction-Associated Steatotic Liver Disease

Study Details

Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis

TyG Index Linked to Higher Fatty Liver Risk

Clinical research that matters. Delivered to your inbox.

Related in Gastroenterology

From Other Specialties